MX2017016590A - Dominios variables simples de inmunoglobulina contra proteina f de rsv. - Google Patents

Dominios variables simples de inmunoglobulina contra proteina f de rsv.

Info

Publication number
MX2017016590A
MX2017016590A MX2017016590A MX2017016590A MX2017016590A MX 2017016590 A MX2017016590 A MX 2017016590A MX 2017016590 A MX2017016590 A MX 2017016590A MX 2017016590 A MX2017016590 A MX 2017016590A MX 2017016590 A MX2017016590 A MX 2017016590A
Authority
MX
Mexico
Prior art keywords
protein
single variable
immunoglobulin single
variable domain
antibody against
Prior art date
Application number
MX2017016590A
Other languages
English (en)
Inventor
Saelens Xavier
Schepens Bert
Rossey Iebe
Graham Barney
Mclellan Jason
Gilman Morgan
Original Assignee
Vib Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57545045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017016590(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP15178653.0A external-priority patent/EP3124042A1/en
Application filed by Vib Vzw filed Critical Vib Vzw
Publication of MX2017016590A publication Critical patent/MX2017016590A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a dominios variables simples de inmunoglobulina (lSVDs) que se dirigen contra virus sincicial respiratorio (RSV). Más específicamente, se refiere a ISVDs que se unen con la forma de prefusión de la proteína de fusión (F) de RSV. La invención también se refiere al uso de estos lSVDs para la prevención y/o el tratamiento de infecciones por RSV y s composiciones farmacéuticas que comprenden estos lSVDs.
MX2017016590A 2015-06-18 2016-06-20 Dominios variables simples de inmunoglobulina contra proteina f de rsv. MX2017016590A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562181522P 2015-06-18 2015-06-18
EP15178653.0A EP3124042A1 (en) 2015-07-28 2015-07-28 Immunoglobulin single variable domain antibody against rsv prefusion f protein
EP15191868 2015-10-28
PCT/EP2016/064218 WO2016203052A1 (en) 2015-06-18 2016-06-20 Immunoglobulin single variable domain antibody against rsv prefusion f protein

Publications (1)

Publication Number Publication Date
MX2017016590A true MX2017016590A (es) 2018-11-09

Family

ID=57545045

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016590A MX2017016590A (es) 2015-06-18 2016-06-20 Dominios variables simples de inmunoglobulina contra proteina f de rsv.

Country Status (18)

Country Link
US (2) US10501528B2 (es)
EP (1) EP3313432A1 (es)
JP (1) JP6836760B2 (es)
KR (1) KR20180056631A (es)
CN (1) CN108472343B (es)
AU (1) AU2016277887B2 (es)
BR (1) BR112017027303A2 (es)
CA (1) CA2989378A1 (es)
CL (1) CL2017003260A1 (es)
HK (1) HK1254779A1 (es)
IL (1) IL256315B2 (es)
MA (1) MA42246A (es)
MX (1) MX2017016590A (es)
MY (1) MY192870A (es)
PH (1) PH12017502356B1 (es)
RU (1) RU2730671C2 (es)
UA (1) UA123584C2 (es)
WO (1) WO2016203052A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3313432A1 (en) * 2015-06-18 2018-05-02 VIB vzw Immunoglobulin single variable domain antibody against rsv prefusion f protein
CN114835802B (zh) * 2019-08-02 2023-07-18 苏州高泓利康生物科技有限公司 针对呼吸道合胞病毒的蛋白结合分子
CN116063468A (zh) * 2022-08-30 2023-05-05 武汉班科生物技术有限公司 中和呼吸道合胞病毒的c-型单域抗体及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP4206231A1 (en) * 2007-12-24 2023-07-05 ID Biomedical Corporation of Quebec Recombinant rsv antigens
AU2009254501B2 (en) 2008-06-05 2014-07-31 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
MX340541B (es) * 2009-06-05 2016-07-13 Alblynx Nv Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio.
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
EP2507262A1 (en) * 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP3313432A1 (en) * 2015-06-18 2018-05-02 VIB vzw Immunoglobulin single variable domain antibody against rsv prefusion f protein

Also Published As

Publication number Publication date
CN108472343B (zh) 2021-12-10
US10501528B2 (en) 2019-12-10
WO2016203052A1 (en) 2016-12-22
AU2016277887A1 (en) 2018-01-18
IL256315B1 (en) 2023-08-01
MA42246A (fr) 2018-05-02
PH12017502356A1 (en) 2018-06-25
CN108472343A (zh) 2018-08-31
JP6836760B2 (ja) 2021-03-03
US20200102374A1 (en) 2020-04-02
CL2017003260A1 (es) 2018-05-11
IL256315B2 (en) 2023-12-01
KR20180056631A (ko) 2018-05-29
RU2018101662A (ru) 2019-07-22
RU2018101662A3 (es) 2019-11-06
EP3313432A1 (en) 2018-05-02
RU2730671C2 (ru) 2020-08-24
US20180179266A1 (en) 2018-06-28
MY192870A (en) 2022-09-13
JP2018524979A (ja) 2018-09-06
BR112017027303A2 (pt) 2018-09-04
HK1254779A1 (zh) 2019-07-26
CA2989378A1 (en) 2016-12-22
PH12017502356B1 (en) 2018-06-25
US11248039B2 (en) 2022-02-15
IL256315A (en) 2018-02-28
AU2016277887B2 (en) 2022-06-09
UA123584C2 (uk) 2021-04-28

Similar Documents

Publication Publication Date Title
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
EA201892251A1 (ru) Стабилизированные растворимые f-белки rsv до слияния
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
EP3411504A4 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USE FOR THE TREATMENT OR PREVENTION OF TYPE-1 DIABETES
EA201792561A1 (ru) Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
WO2014205302A3 (en) Lectin-like oxidized ldl receptor1 antibodies and methods of use
MX2020002406A (es) Anticuerpo anti-epha4.
WO2014205300A3 (en) Lectin-like oxidized ldl receptor1 antibodies and methods of use
MY194084A (en) Interferon beta antibodies and uses thereof
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
PH12015501360A1 (en) Bmp-6 antibodies
WO2016020882A3 (en) Angiopoetin-like 4 (angptl4) antibodies and methods of use
PH12017502356A1 (en) Immunoglobulin single variable domain antibody against rsv prefusion f protein
WO2018088850A3 (ko) Cd40에 특이적으로 결합하는 항체 및 그의 용도
MX2021004356A (es) Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
MX2022000317A (es) Anticuerpos altamente potentes que se unen al receptor de muerte 4 y al receptor de muerte 5.
WO2016135462A8 (en) Treatment